Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Insys Therapeutics, Inc. (INSY)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | S-1/A |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Cost of goods sold | 13.2% | 14.7% | 10.5% | 8.7% | 10.3% | 12.8% | 49.3% | |
| Gross profit | 86.8% | 85.3% | 89.5% | 91.3% | 89.7% | 87.2% | 50.7% | |
| Sales and marketing | 38.2% | 34.7% | 28.7% | 24.4% | 26.5% | 29.4% | 73.7% | |
| Research and development | 70.1% | 44.7% | 30.5% | 17.2% | 15.1% | 8.6% | 40.7% | |
| General and administrative | 47.8% | 33.0% | 17.4% | 19.1% | 20.2% | 16.5% | 52.8% | |
| EBITDA | -80.6% | -135.5% | 13.9% | 34.9% | 36.7% | 36.3% | -105.8% | |
| Depreciation | 9.2% | 5.2% | 2.6% | 1.6% | 1.1% | 1.8% | 10.7% | |
| EBIT | -89.8% | -140.7% | 11.3% | 33.3% | 35.6% | 34.5% | -116.5% | |
| Pre-tax income | -154.0% | -154.4% | 3.5% | 27.5% | 27.9% | 31.8% | -157.5% | |
| Income taxes | -2.3% | 6.9% | 0.3% | 10.0% | 11.5% | -8.9% | 0.0% | |
| Net income | -151.7% | -161.2% | 3.1% | 17.6% | 16.5% | 40.7% | -157.5% | |
|